At next week's workshop on the validation of LC/MS-based protein and peptide tests, the FDA hopes to determine what it needs to demand from test developers.
AstraZeneca'sVarDict was designed to more accurately identify complex tumor mutations in DNA and RNA sequencing data even in samples with low tumor content.
Ebola virus genomes from a post-epidemic flare-up last June showed relatively low genetic divergence compared with related strains from the broader outbreak.
Supported by a $1.5 million grant from NASA, the project aims to characterize microbes in the crew and enclosed environment of the space station.
Both institutions aim to develop novel liquid biopsy approaches that would improve physicians' ability to diagnose, monitor, and treat cancer patients.
Cincinnati Children's Hospital Tests Metagenomic Sequencing to ID Drug-Resistant Bacterial Infections
Researchers found that metagenomic sequencing is better than fecal culture at identifying antimicrobial-resistant bacteria in pediatric patients.
The data, presented at AACR by researchers from Novartis and Foundation Medicine, show that targeted NGS panels can be used to predict genome-wide mutational load.
The firm postponed the launch to enhance Omni's capabilities, in the meantime focusing on opportunities in near-patient testing for its GeneXpert system.
The test was developed by Quest's Focus Diagnostics subsidiary and is the first from a commercial lab to receive an EUA.
The approach is capable of integrating conflicting crosslinking mass spectrometry data to reflect the various conformations a protein complex may take.
Loci identified in a genome-wide association study of women with spontaneous fraternal twin birth offers clues to the hormonal processes behind this propensity.
FedCentric also plans to offer a combined hardware and software solution as well as a cloud-based software option for genomics customers.
The life science and diagnostics company's revenues were short of analyst expectations, though its earnings per share were in line with estimates.
The partners will generate and analyze disease-specific gene expression data to identify likely drug candidates for rare skin diseases.